生殖道靶向检测性能研究

注册号:

Registration number:

ChiCTR2500104642 

最近更新日期:

Date of Last Refreshed on:

2025-06-20 08:45:15 

注册时间:

Date of Registration:

2025-06-20 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

生殖道靶向检测性能研究

Public title:

The study on the performance of targeted next-generation sequencing pathogen detection in reproductive tract

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于靶向病原检测方法的生殖道感染性疾病诊断性能研究

Scientific title:

Research on the Diagnostic Performance of Reproductive Tract Infection Diseases Based on Targeted Pathogen Detection Methods

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

尹玉瑶 

研究负责人:

王辉 

Applicant:

Yuyao Yin 

Study leader:

Hui Wang 

申请注册联系人电话:

Applicant telephone:

+86 150 1143 4311

研究负责人电话:

Study leader's
telephone:

+86 186 1050 3998

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

yuyao1213@126.com

研究负责人电子邮件:

Study leader's E-mail:

whuibj@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国北京市西城区西直门南大街11号北京大学人民医院

研究负责人通讯地址:

中国北京市西城区西直门南大街11号北京大学人民医院

Applicant address:

11 Xizhimen South Street, Xicheng District, Beijing, China

Study leader's address:

11 Xizhimen South Street, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

100044

研究负责人邮政编码:

Study leader's postcode:

100044

申请人所在单位:

北京大学人民医院

Applicant's institution:

Peking University People's Hospital

研究负责人所在单位:

北京大学人民医院

Affiliation of the Leader:

Peking University People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2024PHB587-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学人民医院伦理审查委员会

Name of the ethic committee:

Ethics Review Committee of Peking University People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025-01-15 00:00:00

伦理委员会联系人:

刘慧鑫

Contact Name of the ethic committee:

Huixin Liu

伦理委员会联系地址:

中国北京市西城区西直门南大街11号北京大学人民医院

Contact Address of the ethic committee:

11 Xizhimen South Street, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 8832 4516

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学人民医院

Primary sponsor:

Peking University People's Hospital

研究实施负责(组长)单位地址:

中国北京市西城区西直门南大街11号北京大学人民医院

Primary sponsor's address:

11 Xizhimen South Street, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院

具体地址:

北京市西城区西直门南大街11号北京大学人民医院

Institution
hospital:

Peking University People's Hospital

Address:

11 Xizhimen South Street, Xicheng District, Beijing, China

经费或物资来源:

广州市金圻睿生物科技有限责任公司

Source(s) of funding:

Guangzhou KingCreate Biotechnology Co., Ltd.

研究疾病:

生殖道感染性疾病  

Target disease:

Reproductive tract infectious diseases

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

诊断试验诊断准确性 

Study design:

Diagnostic test for accuracy 

研究目的:

本研究拟通过方法学研究以及临床检出表现对tNGS方法在生殖道感染检测的性能进行系统评估。首先,基于回顾性临床样本建立适用于tNGS检测BV方法的阈值、临床解读和报告形式;其次,基于回顾性/单中心前瞻性临床样本以及多中心前瞻性样本,比较tNGS与常规生殖道感染检测方法对生殖道病原的检出能力和一致性;最后,基于单中心前瞻性样本和多中心前瞻性临床样本、结合临床诊断信息和反馈对tNGS在多种类型阴道炎、HPV、性传播疾病等的诊断性能进行评估。  

Objectives of Study:

This study aims to conduct a systematic evaluation of the performance of tNGS in the detection of reproductive tract infections through methodological research and clinical detection manifestations. Firstly, thresholds, clinical interpretations, and reporting formats suitable for tNGS detection of BV will be established based on retrospective clinical samples. Secondly, the detection capabilities and consistency of tNGS and conventional reproductive tract infection detection methods for reproductive tract pathogens will be compared based on retrospective/single-center prospective clinical samples and multi-center prospective samples. Finally, the diagnostic performance of tNGS in various types of vaginitis, HPV, sexually transmitted diseases, etc. will be evaluated based on single-center prospective samples and multi-center prospective clinical samples, combined with clinical diagnostic information and feedback.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.不符合病原筛查条件的疾病:如非生殖道感染相关疾病,或其他非性传播疾病; 2.入组后48小时内或在入组前使用冲洗剂、阴道除臭剂或阴道内产品; 3.有系统性器质性疾病或精神疾病史的患者.

Exclusion criteria:

1.Diseases that do not meet the criteria for pathogen screening: such as non-genital tract infection-related diseases, or other non-sexually transmitted diseases; 2.Use of douches, vaginal deodorants or vaginal products within 48 hours after enrollment or before enrollment; 3.Patients with a history of systemic organic diseases or mental disorders.

研究实施时间:

Study execute time:

From 2025-06-16 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-06-23 00:00:00 To 2025-12-31 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

优先使用Nugent评分结果,对于4-6分中间态样本则使用Amsel结果进行补充矫正。若tNGS检测结果与BV判断结果不一致,则参考16S rRNA测序结果和临床反馈结合的综合判断标准。 念珠菌属、滴虫、HPV、淋病奈瑟菌、沙眼衣原体、梅毒螺旋体等病原检测的参考方法为临床指南推荐的实验室金标准方法,检测结果评判为阳性或者阴性。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

The Nugent score result should be given priority. For samples with intermediate scores of 4 to 6, the Amsel result should be used for supplementary correction. If the tNGS test result is inconsistent with the BV judgment result, the comprehensive judgment standard combining the 16S rRNA sequencing result and clinical feedback should be referred to. The reference methods for the detection of Candida, Trichomonas, HPV, Neisseria gonorrhoeae, Chlamydia trachomatis, Treponema pallidum and other pathogens are the laboratory gold standard methods recommended by clinical guidelines, and the test results are judged as positive or negative.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

靶向病原基因检测

Index test:

Targeted next-generation sequencing pathogen detection

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

疑似女性生殖道感染或细菌性阴道炎患者

例数:

Sample size:

250

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Patients suspected of having female reproductive tract infections

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

尿路感染或无生殖道感染/细菌阴道炎的患者

例数:

Sample size:

250

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Patients with urinary tract infection or without reproductive tract infection/bacterial vaginitis

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院 

单位级别:

三甲 

Institution
hospital:

Peking University People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

深圳市宝安区妇幼保健院 

单位级别:

三甲 

Institution
hospital:

Shenzhen Bao'an District Maternal and Child Health Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

Nugent评分结果

指标类型:

主要指标

Outcome:

Nugent Score results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

HPV核酸检测结果

指标类型:

主要指标

Outcome:

HPV nucleic acid test results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

念珠菌属核酸检测结果

指标类型:

主要指标

Outcome:

Candida nucleic acid test results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

淋病奈瑟菌核酸检测结果

指标类型:

主要指标

Outcome:

Nucleic acid test result for Neisseria gonorrhoeae

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

沙眼衣原体核酸检测结果

指标类型:

主要指标

Outcome:

Chlamydia trachomatis nucleic acid test result

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

梅毒螺旋体核酸检测结果

指标类型:

主要指标

Outcome:

Nucleic acid test result for Treponema pallidum

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

滴虫核酸检测结果

指标类型:

主要指标

Outcome:

Trichomonas nucleic acid test result

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床诊断是否包括细菌性阴道炎

指标类型:

主要指标

Outcome:

Clinical diagnosis include bacterial vaginitis or not

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

阴道分泌物

组织:

Sample Name:

Vaginal discharge

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 22 years
最大 Max age 55 years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据录入:临床常规检测结果为研究者查询病历系统后手写于病历信息表,而后经Epidata软件录入数据库;测序数据由北京大学人民医院研究者测序得到。 数据核查:Epidata双录入模式核查是否存在录入错误,用Microsoft Office 2016 Excel按照入组标准进行筛选和分析。 数据存档:全部数据整理和保存在北京大学人民医院微生物室的办公电脑和科研专用服务器上。 数据分享:仅向合作单位分享最终评价结果,保护受试者隐私和数据安全。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data entry: The results of routine clinical tests were handwritten in the medical record information table after the investigators inquired the medical record system, and then recorded into the database through Epidata software; The data were sequenced by researchers from Peking University People's Hospital. Data verification: Epidata double-entry mode was used to check whether there were input errors, and Microsoft Office 2016 Excel was used for screening and analysis according to the inclusion criteria. Data archive: All data are organized and stored on the office computer and the dedicated server for scientific research in the Microbiology Room of Peking University People's Hospital. Data sharing: Only the final evaluation results will be shared with the partners to protect the privacy and data security of the subjects.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-06-20 08:45:06